Lili CuiSenior Formulation Scientist, Pharm Sci at Astrazeneca
Dr. Lili Cui obtained her first degree in Pharmaceutics from Shenyang Pharmaceutical University and her PhD in Pharmaceutical Science from King’s College London. During these periods, she has gained wide experience in drug delivery system design, drug formulation and in vitro & vivo delivery. She has developed a set of skills in nanomedicine (liposomes, polymeric nanoparticles, lipopolyplexes etc), nucleic acid delivery, peptide chemistry and cell biology. She started her career as a formulation scientist in Silence Therapeutics GmbH in 2015 where she has broadened her field in nucleic acid drug research and development (lipid nanoparticles, drug conjugate, novel lipids). She moved to AstraZeneca as a senior formulation scientist in 2017. Since then, she has been working on projects involving different nucleic acid-based modalities including mRNA, siRNA, pDNA, Crispr etc and different therapeutic area (oncology, liver, brain etc.). She has successfully delivered a few challenging nucleic acid and protein projects including building up formulation process capability to enable projects. She has been enthusiastic in science and technology and been active in getting involved in internal and external collaborations.